The so-called cognitive enhancers have been widely and increasingly used by healthy individuals who seek improvements in cognitive performance despite having no pathologies. One drug used for this purpose is methylphenidate, a first-line drug for the treatment of attention deficit hyperactivity disorder (ADHD). OBJECTIVE: The aim of the present study was to test the effect of acute administration of varying doses of methylphenidate (10 mg, 20 mg, 40 mg and placebo) on a wide range of cognitive functions in healthy young people. METHODS: A total of 36 young university students and graduates participated in the study. The participants underwent tests of attention and of episodic, and working memory. RESULTS: No differences in performance were observed on any of the tests. There was a dose-dependent (40 mg > placebo) effect on self-reported wellbeing. CONCLUSIONS: According to the recent literature, psychostimulant medications, such as methylphenidate, improve performance when cognitive processes are below an optimal level, which was not the case for the subjects of the present study. We suggest the impression that methylphenidate enhances cognitive performance in healthy young people, justifying its use, may be due to improvements in subjective wellbeing promoted by the drug.
The so-called cognitive enhancers have been widely and increasingly used by healthy individuals who seek improvements in cognitive performance despite having no pathologies. One drug used for this purpose is methylphenidate, a first-line drug for the treatment of attention deficit hyperactivity disorder (ADHD). OBJECTIVE: The aim of the present study was to test the effect of acute administration of varying doses of methylphenidate (10 mg, 20 mg, 40 mg and placebo) on a wide range of cognitive functions in healthy young people. METHODS: A total of 36 young university students and graduates participated in the study. The participants underwent tests of attention and of episodic, and working memory. RESULTS: No differences in performance were observed on any of the tests. There was a dose-dependent (40 mg > placebo) effect on self-reported wellbeing. CONCLUSIONS: According to the recent literature, psychostimulant medications, such as methylphenidate, improve performance when cognitive processes are below an optimal level, which was not the case for the subjects of the present study. We suggest the impression that methylphenidate enhances cognitive performance in healthy young people, justifying its use, may be due to improvements in subjective wellbeing promoted by the drug.
Authors: V S Mattay; J H Callicott; A Bertolino; I Heaton; J A Frank; R Coppola; K F Berman; T E Goldberg; D R Weinberger Journal: Neuroimage Date: 2000-09 Impact factor: 6.556
Authors: Danielle C Turner; Andrew D Blackwell; Jonathan H Dowson; Andrew McLean; Barbara J Sahakian Journal: Psychopharmacology (Berl) Date: 2004-08-27 Impact factor: 4.530
Authors: Cristina Lanni; Silvia C Lenzken; Alessia Pascale; Igor Del Vecchio; Marco Racchi; Francesca Pistoia; Stefano Govoni Journal: Pharmacol Res Date: 2008-02-15 Impact factor: 7.658
Authors: Nora D Volkow; Gene-Jack Wang; Joanna S Fowler; Frank Telang; Laurence Maynard; Jean Logan; Samuel J Gatley; Naomi Pappas; Christopher Wong; Paul Vaska; Wei Zhu; James M Swanson Journal: Am J Psychiatry Date: 2004-07 Impact factor: 18.112